“Deucravacitinib in Plaque Psoriasis: 3-year Safety and Efficacy Results from the Phase 3 POETYK PSO-1 and PSO-2 Trials” (2024) SKIN The Journal of Cutaneous Medicine, 8(2), p. s366. doi:10.25251/skin.8.supp.366.